Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PAES of Buccalin in prophylaxis of recurrent lower respiratory tract infections
2024-512937-34-00Phase 4Authorised
- Sponsor
- Laboratorio Farmaceutico SIT
- Start
- Oct 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 4, randomised, double-blind trial in pulmonary infection comparing Buccalin with Placebo (2 arms). Primary endpoint: Number of infection episodes during 12-month treatment period. Planned start Oct 2024; status: authorised.
02
Drugs
Buccalin
03
Conditions
pulmonary infection
Beyond the preview
Go deeper on 2024-512937-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512937-34-00.